Poniard Pharmaceuticals Cuts Positions, Focuses on Oncology

Poniard Pharmaceuticals Inc. said it will concentrate its cash resources on the clinical and commercial development of its late-stage oncology candidate, picoplatin, and cut about 12 percent of its staff, or eight employees.
San Francisco Business Times